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Abstract 
Carboplatin (diammine [1,1 cyclobutane dicarboxylato 
(2)-0,0'] platinum) is an anti-cancer agent which can be 
toxic to the inner ear. We have explored the nature of this 
ototoxicity in the chinchilla. In this species, initial 
degenerative changes appear to be restricted to the inner 
hair cell (IHC) regions of the organ of Corti. This finding 
is intriguing and unusual since all other known ototoxic 
drugs, such as aminoglycosides, are predominantly associ-
ated with outer hair cell damage. 
In the present study, the mechanism of ototoxicitywas 
investigated by comparing two different routes of carbo-
platin administration. Carboplatin was administered either 
intravenously (i. v .) or intraperitoneally (i.p.). The mode 
of administration influenced electrophysiological and mor-
phological changes. Hearing thresholds were elevated in 
the i.v. group significantly more than in the i.p. group at 
all tested frequencies. The degree of hair cell damage was 
evaluated by scanning electron microscopy at four fre-
quency regions in each cochlea. IHC damage in the i. v. 
group was significantly more severe than in the i.p. group. 
Carboplatin effects on a different species, the guinea 
pig, were also determined to clarify interspecies differ-
ences. In the guinea pig, outer hair cell damage occurred 
sporadically and inner hair cells remained intact. In con-
trast, chinchilla inner hair cells are susceptible to the 
ototoxic effects of carboplatin. The degree of hair cell 
damage appears to be dependent on the peak level of carbo-
platin rather than on the total dose. This animal model 
provides a new tool for the investigation of inner and outer 
hair cell function. 
Key Words: Scanning electron microscopy, chinchilla, 
organ of Corti, inner hair cell, carboplatin, ototoxicity. 
• Address for correspondence: 
Sachio Takeno, 
Department of Otolaryngology, 
The Hospital for Sick Children, 
555 University Avenue, 
Toronto Ontario, Canada, MSG 1X8 
Telephone Number: (416) 813-6551 
FAX Number: (416) 813-5036 
97 
Introduction 
The development of the platinum group of anti-cancer 
drugs originated in 1965 with pioneering work in which the 
inhibitory effects of soluble platinum salts on cP!! ~i vi~ion 
of Escherichia coli were discovered (Rosenberg et al., 
1965, 1969). Cisplatin was the first and the most potent 
drug from the platinum group and has been used for over 
a decade for the treatment of various cancers. However, 
cisplatin has serious dose-limiting side effects of nephro-
toxicity and neurotoxicity. Ototoxicity, in the form of 
dose-dependent sensorineural hearing loss, is another major 
side effect of cisplatin treatment. In an attempt to reduce 
the dose-limiting toxicities, a second generation of platinum 
compounds was developed and entered clinical trials. 
Carboplatin (diammine [1, 1 cyclobutane dicarboxylato 
(2)-0,0'] platinum, CBDCA) is one of the cisplatin ana-
logues. Carboplatin expresses its anti-neoplastic effect by 
forming inter/intra-strand DNA cross-links when converted 
into a hydrated species (van Hennik et al., 1987). In clini-
cal experience, carboplatin causes significant, dose-limiting, 
myelosuppression but is reported to be less nephrotoxic and 
ototoxic than cisplatin. The incidence of hearing loss in 
humans caused by carboplatin, generally restricted to the 
higher frequencies, ranges from Oto 19% (Calvert et al., 
1982;Kennedyeta/., 1990;Macdonaldetal., 1994). This 
value is less than that of cisplatin which ranges from 25 to 
100% (Lippman et al., 1973; Piel et al., 1974; Strauss et 
al., 1983; Kopelman et al., 1988; Myers et al., 1991). 
The large variability in reported incidence of ototoxicity is 
influenced by: mode of administration, cumulative total 
dosage and maximal single dosage, age of patient, and pres-
ence or absence of a preexisting hearing defect. In experi-
mental animal models, ototoxic effects of these two plati-
num compounds on the organ of Corti have been character-
ized by a range of outer hair cell (OHC) damage across 
various species including guinea pigs (Estrem et al., 1981; 
Nakai et al., 1982; Tange et al., 1982; Schweitzer et al., 
1984, 1986; Marco-Algarraet al., 1985; Saito et al., 1989; 
McAlpine and Johnstone, 1990; Tautly et al., 1992), mon-
keys (Stadnicki et al., 1975), and rats (Anzai et al, 1987). 
The ototoxic potential has also been analyzed using organ 
culture models (Ann.iko and Sobin, 1990). All these data 
have consistently indicated that the predominant effect of 
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both compounds is OHC degeneration, carboplatin being 
less ototoxic than cisplatin. 
We have recently found that in chinchillas carboplatin 
is highly ototoxic (Wake et al., 1993; Takeno et al., 1994). 
A single intravenous administration of 200 to 400 mg/m2 
carboplatin, which is equivalent to the clinically suggested 
therapeutic dose, is enough to induce significant hearing 
threshold elevation as determined by auditory brainstem 
evoked responses (ABR). Furthermore, the degenerative 
changes seen in the organ of Corti are highly selective to 
the inner hair cells (IHCs). An IHC lesion is very unusual 
since all known cochleotoxic drugs in any other animal 
model predominantly and initially affect OHCs. While IHC 
loss due to cisplatin ototoxicity has been observed both in 
humans (Wright and Schaefer, 1982; Strauss et al., 1983) 
and in rhesus monkeys (Stadnicki et al., 1975), it always 
occurred subsequent to extensive OHC damage. To the 
best of our knowledge, the only combination producing a 
lesion with missing IHCs and intact OHCs is carboplatin in 
chinchillas. 
In the present study, we describe detailed morphologi-
cal features of this intriguing animal model using scanning 
electron microscopy (SEM). The results are compared with 
physiological data obtained by ABR recordings. In the 
chinchilla, two different routes of administration of carbo-
platin (intravenous: i.v.; and intraperitoneal: i.p.) were 
employed to determine potential differences in ototoxic ef-
fects. In an additional study, guinea pigs were treated with 
the same dosage of carboplatin to clarify the unique inter-
species difference between chinchillas and other animals. 
Materials and Methods 
Adult chinchillas and albino (Hartley) guinea pigs, free 
from ear disease, were used in this study. Three treatment 
groups were set up as follows: A) 6 chinchillas treated with 
carboplatin injected into the internal jugular vein (i. v .); B) 
6 chinchillas treated with i.p. injection of carboplatin; and 
C) 6 albino guinea pigs treated with i.p. injection of 
carboplatin. In all groups, carboplatin in 5 % dextrose was 
administered as a single injection at the dose of 400 mg/m2 
(total volume 3 ml). This is equivalent to the maximum 
therapeutic dose clinically scheduled for single-agent 
regimens as a single i. v. injection. Additionally, two 
control studies were carried out: D) chinchillas identically 
treated with 3 ml i.v. injection of 5% dextrose without 
carboplatin; and E) guinea pigs treated with 3 ml i.p. 
injection of 5 % dextrose without carboplatin. 
Carboplatin for the study was supplied by Bristol 
Myers Canada (Paraplatin-AQ). The surface area of the 
animals was estimated using the formula of Yates and 
Kugler (1986). ABR recordings of all animals were carried 
out prior to and two weeks after treatment. 
ABR recordings were obtained from animals lightly 
anesthetized using ketamine (15 mg/kg), xylazine (2.5 
mg/kg) and atropine (0.004 mg/kg). Skin needle electrodes 





Figure 1. Frequency position map of the chinchilla coch-
lea. Characteristic frequencies are assigned along the 
cochlea length according to the data of Eldredge et al. 
(1981). Note that 8, 4, 2 kHz regions are located in the 
basal turn, and 1, 0.5 kHz regions are included in the 
second turn. RW: round window. OW: oval window. 
Sound stimuli were tone pips (2 ms rise/fall, 2 ms plateau) 
at octave intervals between 0.5 and 8 kHz. These signals 
were calibrated in an artificial (chinchilla) ear using a 
standard reference. Sound was delivered free-field in a 
sound attenuated room. Potentials were band pass filtered 
(150 Hz - 3 kHz) and amplified conventionally. After ana-
logue to digital conversion and artifact rejection, signals 
were averaged over 300 sweeps in a 25 ms window (Cam-
bridge Electronic Design 1401 intelligent interface with 
80286 microprocessor host). ABR waveform amplitudes 
were measured over a range of stimulus intensities allowing 
threshold determinations. Bilateral pre- and post-treatment 
ABR audiograms were determined for each animal. 
All animals were prepared for morphological evalua-
tion of the cochleas immediately following the final record-
ing sessions. Under deep anesthesia with sodium pentobar-
bital (50 mg/kg), cardiac perfusion was carried out with 
fixative (1.25 % glutaraldehyde, 1 % paraformaldehyde in 
0.1 M phosphate buffer, pH 7.4), and the temporal bony 
capsules were removed. Cochleas were exposed and per-
fused with 2.5 % glutaraldehyde in 0.1 M phosphate buffer 
through the oval and round windows. The specimens were 
then prepared for SEM. After initial fixation, the speci-
mens were rinsed in 0.1 M phosphate buffer and conductive 
stained with 1 % tannic acid for 30 minutes followed by 
post-fixation with 0.5 % osmium tetroxide for 15 minutes. 
After dehydration through a graded ethanol series (50, 70, 
80, 90, 95 and 100% twice), specimens were immersed in 
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Figure 2. ABR threshold elevation values (mean ± stand-
ard deviation, S.D.) after carboplatin treatment for experi-
mental groups A, B, and C (10 cochleas in each group). 
a) Group A (i.v. in the chinchilla) shows the most remark-
able changes at all frequencies. b) Group B (i.p. in the 
chinchilla) shows less hearing loss compared to Group A. 
c) Group C (i.p. in the guinea pig) developed only minimal 
changes in threshold elevation. Statistical differences 
observed in the chinchilla between group A (i. v .) and group 
B (i.p.) are indicated by: * (p < 0.05), ** (p < 0.01); 
(two-sample t-test). 
amyl acetate for 30 minutes then critical point dried from 
CO2. Specimens were sputter coated with 30 A thick gold. 
The extent of IHC and OHC damage observed by SEM 
was assessed in specific regions of the cochlea and com-
pared to the corresponding ABR data. In the chinchilla, 
cochlear frequency-place maps derived by Eldredge et al. 
(1981) were used. Hair cell damage was assessed in the 
0.5, 1, 2, 4 and 8 kHz regions (Fig. 1). In the guinea pig, 
the mid-portion of each turn of the cochlea was observed as 
described elsewhere (Saito et al., 1989). At each assessed 
location, an area of the organ of Corti containing 100 IHCs 
and 100 each first, second and third row OHCs was exam-
ined to determine the degree of damage in each of the four 
rows. Hair cell condition was graded using the following 
criteria: Grade O = normal to slight damage (less than 20 % 
disruption of the stereocilia); Grade 1 = moderate damage 
(disruption of stereocilia but with less than 50% of stereo-
cilia missing); Grade 2 = severe damage (less than 50% 
surviving stereocilia); and Grade 3 = presence of fusion/ 
extrusion bodies, or total loss of stereocilia or hair cell (this 
grading scheme was modified from that of Fukushima et 
al., 1990). Final hair cell damage scores are calculated 
according to the formula below and expressed as a percent-
age (total loss = 100%). 
(total grade number) x 100 
(number of evaluated hair cells) x 3 
All procedures using animals were carried out with 
strict adherence to standards implemented by local Animal 
99 
Care Committees and following national guidelines issued 
by the Canadian Council on Animal Care, as well as local 
(Ontario) legislation. 
Results 
The single administration of 400 mg/m 2 carboplatin 
caused the death of one subject in each group due to acute 
toxicity. The necropsy data suggested the existence of 
severe pulmonary infection triggered by myelosuppression. 
Therefore, 10 cochleas in total (5 animals) from each group 
were assessed for ABR threshold elevation and hair cell 
condition. The general condition of the surviving carbo-
platin treated animals was good throughout the experiments. 
They appeared healthy with normal behavior. 
ABR threshold shifts 
In Figure 2, the mean values (± 1 S.D.) of post-treat-
ment ABR threshold elevations (i.e., the difference between 
the pre- and post-treatment threshold level in each subject) 
are plotted for the three experimental groups. The majority 
of cochleas from each group showed differences in pre- and 
post-treatment thresholds. Group C (i.p. injection in the 
guinea pig; right-hand plot) developed only minimal 
changes in hearing sensitivity with the administration of 400 
mgtm 2 carboplatin. In this group, less than 10 dB thresh-
old elevation was found across the tested frequencies. In 
group B (i.p. injection in the chinchilla; center plot), the 
mean threshold elevation ranged from 7.5 dB to 15.5 dB, 
the greater shifts occurred at higher frequencies. 
The most significant threshold elevations occurred in 
group A (i. v. injection of carboplatin in the chinchilla, left-
hand plot). In this group, seven of ten cochleas sustained 
severe hearing loss (more than 40 dB) including unrecorda-
ble potentials especially at high frequencies. A large 
inter-individual variability was also noted in this group as 
indicated by the standard deviation bars. Similar to group 
B, hearing losses are greater at higher frequencies. 
Threshold elevations at all frequencies of group A were 
significantly greater (p < 0.01 at 0.5, 1, 4 and 8 kHz; 
0.01 < p < 0.05 at 2 kHz; two-sample t-test) than group 
B. Differences in threshold shifts (averaged of all fre-
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observed in some subjects. Thus, 4 of 5 in group A, 2 of 
5 in group B, and 1 of 5 in group C revealed more than 10 
dB disparity between sides when averaged across fre-
quencies. 
Scanning electron microscopy morphology 
After ABR measurements were obtained, all cochleas 
were examined by SEM to assess the relationship between 
physiological and morphological findings. The most re-
markable difference in morphological abnormalities between 
the two different species (chinchillas and guinea pigs) 
following carboplatin treatment was in the type of damage 
to the organ of Corti. In the chinchilla (groups A and B), 
the IHC region was predominantly affected, with OHCs be-
ing damaged to a lesser degree. On the contrary, in the 
guinea pig (group C), IHCs remained intact in all subjects, 
and only mild sporadic degeneration was observed in the 
OHC area. In Figure 3, the degrees of damage suffered by 
IHCs and OHCs are summarized for four frequency regions 
in the chinchilla and at three turns in the guinea pig. Fig-
ures 4, 5, and 6 are scanning electron micro graphs showing 
Figure 3. Relative proportion of inner and outer hair cell damage (mean± S.D.) at each sam-
pled location for experimental groups A, B, and C; (IO cochleas in each group). a) Group A 
100 '------'------' (i. v. in the chinchilla) shows the most extensive destruction of sensory epithelium both in inner 
IHC OHC 
c) Group C 
and outer hair cell regions. b) Group B (i.p. in the chinchilla) also shows similar patterns of 
hair cell damage to those of group A, but the degree of IHC damage is much lower. c) Group 
C (i.p. in the guinea pig) developed only minimal cytoarchitectural changes in the hair cells. 
The changes observed in the two chinchilla groups of different drug administration routes 
(groups A and B) are significantly different: * (p < 0.05); ** (p < 0.01); (two-sample t-test). 
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Carboplatin Induced Inner Hair Cell Damage 
Figure 4. Scanning electron photomicrographs of the 
organ of Corti showing representative samples from group 
A. (a) In this 8 kHz region, i. v. injection of carboplatin 
caused almost total IHC destruction. Characteristic forma-
tion of fusion/extrusion bodies is demonstrated on the sur-
face of reticular lamina. The OHCs remain intact in this 
area (IHC loss; 97%, OHC loss; 10%). (b) Two of ten 
cochleas in group A showed considerable OHC degenera-
tion along with complete IHC loss. This relatively rare 
case is demonstrated in the 4 kHz region (IHC loss: 94 % ; 
OHC Joss: 30%). 
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Figure 5. Scanning electron photomicrographs showing 
representative samples from group B. (a) The gross view 
of the 4 kHz region in this subject demonstrates a Joss of 
> 50% IHCs with a normal OHC population. In general, 
i.p. injection of carboplatin induced milder damage to the 
hair cells than i.v. injection. Furthermore, formation of 
fusion/extrusion bodies, which occasionally occurred subse-
quent to IHC degeneration in i.v. cases, is not commonly 
detected in i.p. cases (IHC loss: 67%; OHC Joss: 0.6%). 
(b) In this 2 kHz region of group B, moderately preserved 
IHCs are demonstrated (IHC loss: 33 % ; OHC Joss: 0.8%). 
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Figure 6. Scanning electron micrographs showing representative samples from group C. (a) The most intriguing finding here 
is that carboplatin induces no IBC damage in the guinea pig in complete contrast to the chinchilla. This micrograph from the 
3rd turn of a guinea pig's cochlea demonstrates an intact row of IBCs with occasionally missing OHCs (IHC loss: 1 % ; OHC 
loss: 2 % ). (b) Mildly scattered loss of OH Cs is observed in the I st turn region of this specimen (IHC loss: 0 % ; OHC loss: 
4%). 
representative samples of the damaged sensory epithelium 
from treatment groups A, B, and C respectively. 
Inner hair cell damage was greatest in group A animals 
at all frequency locations. Mean values of group A damage 
scores ranged from 50% at 1 kHz to 76% at the 8 kHz re-
gion. A general finding of carboplatin ototoxicity in the 
chinchilla (both i. v. and i.p. treated subjects) was that more 
IBC damage was noted in the higher frequency regions than 
in the apical lower frequency areas. Group A animals have 
a high degree of variability of inter-cochlea susceptibility to 
IBC damage (Fig. 3a), as is also reflected in the variability 
in ABR threshold shifts (Fig. 2a). In group B, the pattern 
of hair cell damage caused by carboplatin was similar to 
that of group A in all four frequency areas. However, the 
degree of IBC damage was less (from 22 % damage at 1 
kHz to 46% at the 8 kHz region) than that of group A, and 
the variability between cochleas was reduced particularly in 
the lower frequencies. OHC damage in this group was 
minimal with generally less than 2 % OHC damage ob-
served across all frequencies. The degree of IBC and OHC 
degeneration assessed at four frequency regions was statis-
tically different from those of group A (p < 0.01 at 1, 2, 
4, 8 kHz for IHCs and at 8 kHz for OHCs; 0.01 < p < 
0.05 at 1, 2, 4 kHz for OHCs; two sample t-test). The 
guinea pigs of group C did not show significant cytoarchi-
tectural changes in the sensory epithelium except for some 
occasional scattered loss of OHCs. In general, there was 
less than 5 % OHC damage and almost no IHC damage in 
this group. 
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Figure 7 summarizes the distributions of the surviving 
three rows of OHCs in each group. In general, carboplatin 
toxicity results in only minimal damage to OHCs of the 
three rows in groups B and C. In group A, two of ten 
cochleas indicate significant OHC loss (20-30% OHC dam-
age), which is dominant toward the basal region and more 
pronounced in the first row. IHCs of these subjects are 
more extensively damaged (70-90% damage) than others in 
the group. Results of the statistical analysis (ANOVA; sin-
gle factor) revealed no significant difference in damage to 
OHCs among the three rows either at any frequency region 
or at any turn in the three groups. 
The control studies in both species gave the following 
results: normal animals treated with 5 % dextrose, either 
i. v. (chinchillas) or i.p. (guinea pigs), showed no audio-
metric threshold elevation and retained morphologically 
normal cochleas. 
Discussion 
Comparison of drug administration routes 
In the present study, two different routes of adminis-
tration of carboplatin were employed in the chinchilla, and 
the resulting physiological and morphological changes were 
analyzed statistically. The mode of administration of plati-
num compounds has been previously investigated by others 
with respect to both the therapeutic index in treating disease 
and systemic toxicity, especially nephrotoxicity, bone mar-









































Carboplatin Induced Inner Hair Cell Damage 
!5~~? 
6 3 4.8 6 7 1 4.8 





1.5 1 1.4 





























1 k region 2k region 
=+---- • -z+a :E • / .~ ~;f= 
1.3 1 1 
2.6 1.6 1.9 
4k region Bk region 
OHC10HC20HC3 OHC10HC20HC3 
a) Group A 
OHC10HC20HC3 OHC10HC20HC3 
b) Group B 
~ • • -




4.4 3.1 6.2 
3rd turn 
OHC1 OHC2 OHC3 
c) Group C 
*~ 
2.6 4.3 3.4 
2nd turn 
OHC1 OHC2 OHC3 
In dogs which received a single cisplatin i.v. injection, 
the serum concentration showed a peak level after a few 
minutes (Litterst et al., 1976; Pretorius et al., 1981). The 
distribution was a distinct biphasic clearance pattern with a 
short initial half-time (less than 1 hour) and a prolonged 
biologic elimination phase (about 5 days). After i.p. ad-
ministration of cisplatin, the initial concentration of plati-
num compounds within the peritoneal cavity exceeds the se-
rum level, and a portion of the i.p. injected dose is gradual-
ly absorbed from the peritoneal cavity over the course of 
several hours. Serum platinum reaches peak levels around 
4 hours after i.p. injection in dogs and then decreases in a 
way similar to the i. v. levels. These authors also reported 
that peak serum levels after i. v. injection were around ten 
times higher than after i.p. injection of an equal dose. The 
same phenomenon has been also reported in humans (Jones 
et al., 1978). 
Peak plasma concentrations and clearance rates differ 
between species. Van Hennik et al. (1987) reported that, 
after i. v. administration of 495 mg/m2 carboplatin, the peak 
Figure 7. Degrees of damage in each of the three OHC rows (mean ± S.D.) at each sampled 
frequency location of the cochlea in groups A, B and C (10 cochleas in each group). a) In 
group A (i. v. in the chinchilla), two of ten cochleas show noticeable (20-30%) OHC damage, 
while the others maintain well-preserved OHCs. b) Group B (i.p. in the chinchilla) shows al-
most intact OHCs in all subjects. c) In group C (i.p. in the guinea pig), despite totally intact 
JHCs, about 5 % OHC damage was observed across four frequency regions as depicted in 
Figure 6. In all three groups, no significant increase in damage to OHCs of any particular row 
is detected at the locations demonstrated here (ANOVA; single factor). 
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platinum level measured in mice was nearly 7-fold higher 
than in humans, but the initial half-time was 6 times shorter 
in mice. In the present study, we did not measure actual 
levels of carboplatin with respect to serum and inner ear 
tissues. However, based on the above mentioned studies, 
we expect the peak serum level to be significantly higher in 
the i.v. injected group than in the i.p. injected group. 
The route of administration (i.v. versus i.p.) does not 
affect systemic toxicity with reference to renal and bone 
marrow functions in dogs treated with a relatively high 
dose (3 mg/kg) of cisplatin for that species (Pretorius et 
al., 1981). However, regarding ototoxicity, Laurell and 
Engstrom (1989) reported different effects of cisplatin 
between a single high-dose i.v. injection and multiple low-
dose i.p. injections in guinea pigs. With i. v. injection, the 
loss of endocochlearpotentials (EP) was detected as well as 
ABR threshold elevation, while no permanent change in EP 
was seen with multiple low-dose treatment despite the 
occurrence of a more profound hearing loss. Our present 
study aiso showed significant difference in carboplatin oto-
toxicity, both physiologically and morphologically, between 
the two administration routes. ABR threshold elevation in 
chinchillas induced by i. v. carboplatin was greater than that 
by i.p. injections at all measured frequencies. 
Consistent with degree of auditory threshold elevation, 
we observed that pathological changes to the organ of Corti 
differ in degree of damage to the hair cells between the i. v. 
and i.p. treated groups. We might conclude that the signif-
icant differences in ABR threshold elevations primarily 
reflect degenerative changes occurring in the IHC regions. 
However, after administration of 400 mg/m2 i. v. carbo-
platin in chinchillas, in addition to the total loss of IHCs, 
degenerative changes were occasionally seen in the stria 
vascularis. The observed pathology included gross capil-
lary dilatation, widening of intercellular spaces and margi-
nal cell flattening (Wake et al., 1993). Marginal cells of 
the stria vascularis have also been documented as a target 
of platinum compounds by others (Tange and Vuzevski, 
1984; Kohn et al., 1988, 1991). In relation to stria! dam-
age, Konishi et al. (1983) reported a decrease in the endo-
cochlear potential and suppression of the cochlear micro-
phonic in cisplatin treated guinea pigs. The stria vascularis 
seems to be less susceptible than hair cells of the organ of 
Corti, and the stria! degeneration might manifest itself un-
der limited conditions when exposed at relatively high con-
centrations of platinum compounds (Nakai et al., 1982). 
On balance, however, the ototoxic effects of carboplatin in 
the chinchilla are mainly on the IHC, and the effects seem 
to be dependent on the peak levels of the drug rather than 
the total dosage. Future studies should include correlation 
of hair cell damage with drug levels and with other poten-
tial toxicities, after acute and chronic treatment. 
Selective me damage in the chinchilla 
Another remarkable aspect of the present study is the 
distinct interspecies difference between the chinchilla and 
the guinea pig. Both species are commonly used as experi-
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mental animal models of various ototoxic agents to supple-
ment data from human clinical studies. In guinea pigs 
treated with carboplatin, hair cell damage occurred only 
sporadically in the OHC regions, and the IHC remained in-
tact, confirming previous observations (Schweitzer et al., 
1986; Saito et al., 1989; Tautly et al., 1992). Tautly et al. 
(1992) reported that carboplatin at cumulative doses of 120 
mg/kg i.p. in the guinea pig induced ABR threshold shifts 
ranging from 8 to 15 dB across the frequencies, consistent 
with our data. Their hair cell counts in the carboplatin-
treated animals also showed less than 15 % loss of the nor-
mal population and this was limited to the OHC area. On 
the other hand, in our study, chinchillas, after i.p. carbo-
platin administration with the same dose and time schedule, 
showed degenerative changes restricted to the IHC regions. 
Mean IHC loss ranged from 22 to 46 % with preference to-
ward the basal turn, while more than 98 % of OH Cs sur-
vived at all locations. Degrees of IHC damage were char-
acterized by separation and splaying of stereocilia, bleb 
formation on the plasma membrane, presence of fusion/ex-
trusion bodies into endolymphatic space, and total loss of 
IHCs. It should be noted that the morphological changes 
observed here have some shared similarity with those in-
duced by cisplatin in guinea pigs, an animal model which 
has been most thoroughly studied (Comis et al., 1986; 
Barron and Daigneault, 1987). Comis et al. (1986) also in-
dicated a significant increase in calcium levels inside the 
distorted hair cells during early periods after single-dose 
cisplatin treatment and the onset of hair cell degeneration 
closely associated with the calcium increase. Since plati-
num compounds are known to inactivate various plasma 
membrane enzymes and, as a result, affect cellular homeo-
static functions (Aggarwal and Niroomand-Rad, 1983; 
Aggarwal, 1993), it has been suggested that in both animal 
models changes such as the formation of blebs and fusion/ 
extrusion bodies may be due to the primary effect of the 
drugs which directly act on hair cell metabolic mechanisms. 
In addition to providing insights into the mechanisms 
of drug ototoxicity, we believe that the model presented 
here will allow further elucidation of cochlear mechanisms. 
Just as selective OHC destruction using aminoglycosides 
has revealed the contributions of hair cell groups in the 
transduction process (Dallos and Wang, 1974; Evans and 
Harrison, 1976; Zwislocki, 1984), the present model pro-
vides for a complementary study examining the function of 
the cochlea in the absence of IHCs. 
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Discussion with Reviewers 
Y. Nakai: Are there any special degenerative features in 
the inner hair cell cytoplasm, nerve endings or fibers asso-
ciated with the ototoxic effects of carboplatin? 
S.D. Comis: Are the authors planning to confirm by trans-
mission electron microscopy (TEM) that there are no unto-
ward changes in the morphology of the OHC synapse-nerve 
fiber unit after carboplatin administration? It would be 
interesting to know if there are any degenerative changes in 
the nerve fibers associated with the IHCs. 
Authors: Our previous study (Wake et al., 1993) demon-
strated abnormal IHC stereocilia with evidence of fusion/ 
extrusion bodies by light microscopy (LM) observations. 
OHC stereocilia and cell bodies appeared normal at the LM 
level. In addition, the spiral ganglion showed scattered 
Type I cell degenerative changes with pyknosis or nuclear 
disruption. Those features were observed two weeks after 
a single i.v. treatment of 400 mg/m 2 carboplatin. We are 
currently preparing specimens for TEM to investigate the 
ultrastructure of selectively damaged IHCs and their asso-
106 
ciated nerve endings, both at acute and chronic stages. The 
results will be reported in the near future. 
Y. Nakai: Do the authors have any idea why IHCs in the 
chinchilla are more vulnerable than OHCs to carboplatin? 
S.K. Aggarwal: Do the authors expect the mechanism for 
hair cell damage after carboplatin to be the same as after 
cisplatin treatment, i.e., through intracellular calcium 
changes? 
G. Laurell: The present study describes species differences 
between the chinchilla and the guinea pig. Can the selective 
IHC damage in the chinchilla be explained by a specific 
drug distribution inside the cochlea or can it be explained by 
cellular mechanism of carboplatin ototoxicity at the IHC 
level? 
V.G. Schweitzer: It would be interesting to compare the 
toxicities in the chinchilla model of carboplatin versus cis-
platin including: morphological and electrophysiological 
function of OHCs and IHCs; serum drug levels after acute 
dosing; and other types of toxicities manifested (nephro-
toxicity, neurotoxicity, bone marrow suppression, GI 
toxicity, as well as ototoxicity). 
Authors: We do not have any direct evidence to postulate 
on the mechanism of selective THC damage in the chinchil-
la. However, we would like to draw attention to the fact 
that cisplatin in the chinchilla does cause the usual OHC 
damage (Gratton et al., 1990; our preliminary data). The 
effect of cisplatin on the chinchilla cochlea is similar to its 
effect on the guinea pig as reported by Comis et al. (1986); 
they noted significant increases in calcium levels in abnor-
mal outer hair cells of the guinea pig cochlea. It is possible 
to speculate that the difference in molecular structure be-
tween carboplatinand cisplatin causes discriminativeaffinity 
for the two types of cochlea hair cells in the chinchilla. The 
combination of these two toxic effects in the same species 
are amazing and worth further investigation since they may 
enable us to elicit the key mechanism of platinum oto-
toxicity. 
S.D. Comis: Do the authors have any data regarding the 
possible long term (many months) effects of carboplatin on 
OHCs? 
Authors: We are maintaining a small colony of carboplatin 
treated chinchillas to investigate long term effects of the 
drug. Preliminary data has shown that the selective IHC 
damage can be maintained with complete OHC preservation 
at least six months. Results of this chronic study will be 
reported in the future. 
S.D. Comis: Have any studies been performed on these 
chinchillas to look for changes in otoacoustic emissions? 
V.G. Schweitzer: Do the authors consider the use of addi-
tional modalities to evaluate inner hair cell function, such as 
single unit hair cell recording and evaluation of the IHCs on 
a subcellular level? 
Authors: We agree that studies of both single unit hair cell 
recording and otoacoustic emissions using this animal model 
would be of great value. The project is currently m 
progress and results will be reported in the future. 
